HIMS241129C28000
- 3.60
- +3.25+928.57%
Hims & Hers Health Newsroom
Hims & Hers Health Options Spot-On: On November 25th, 203.78K Contracts Were Traded, With 629.63K Open Interest
Dow, S&P, and Nasdaq Ended Higher to Start the Holiday Shortened Trading Week
Hims & Hers Health Trading 22% Higher, WIth Gains Attributed to FDA Nominee
Trump's Made His Health Picks. What They Mean for the Sector. -- Barrons.com
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Hims & Hers up 18% Amid Optimism for Compounders With Makary FDA Pick
Unusual Options Activity: SPOT, MOD and Others Attract Market Bets, SPOT V/OI Ratio Reaches 90.4
Hims & Hers Health Gain on Potential FDA Leadership Ties
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Applied Digital And Hims & Hers Health Are Among Top 9 Mid-Cap Gainers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?
Hims & Hers Health Options Spot-On: On November 22nd, 119.74K Contracts Were Traded, With 644.77K Open Interest
Unusual Options Activity: BNS, XP and Others Attract Market Bets, BNS V/OI Ratio Reaches 166.7
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Hims & Hers Health Shares Rise Thursday Amid Extension of FDA Decision
Hims & Hers Health Expands Board With New Appointment
Citi Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $24
Hims & Hers Health Options Spot-On: On November 21st, 99,200 Contracts Were Traded, With 627.89K Open Interest
Express News | Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or...
Hims & Hers Closes up 10% as Lilly Tirzepatide Compounding Dispute Resolution Delayed
Hold Rating on Hims & Hers Health Amidst Regulatory Uncertainty and Market Risks